UG Healthcare Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Keck Keong Lee

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	8.2yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	4.8yrs
Yönetim Kurulu ortalama görev süresi	5.5yrs

Son yönetim güncellemeleri

Recent updates

CEO

Keck Keong Lee (70 yo)

8.2yrs

Görev süresi

Mr. Keck Keong Lee has been the Chief Executive Officer at UG Healthcare Corporation Limited since October 19, 2016 and its Executive Director since November 20, 2014 and served as its Non-Executive Direct...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Keck Keong Lee	CEO & Executive Director	8.2yrs	Veri yok	Veri yok
Jun Yih Lee	Finance Director & Executive Director	5.3yrs	Veri yok	0.46% SGD 341.4k
Jun Linn Lee	COO & Executive Director	4.2yrs	Veri yok	0.36% SGD 266.0k
Pek Wee Wong	Head of Manufacturing	no data	Veri yok	Veri yok
Mei Low	Company Secretary	3.5yrs	Veri yok	Veri yok

4.8yrs

Ortalama Görev Süresi

48.5yo

Ortalama Yaş

Deneyimli Yönetim: 8K7 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Keck Keong Lee	CEO & Executive Director	10.1yrs	Veri yok	Veri yok
Jun Yih Lee	Finance Director & Executive Director	10.1yrs	Veri yok	0.46% SGD 341.4k
Jun Linn Lee	COO & Executive Director	10.1yrs	Veri yok	0.36% SGD 266.0k
Cheong Yan Law	Independent Non-Executive Director	no data	Veri yok	Veri yok
Fook Choy Wong	Independent Non-Executive Chairman	no data	Veri yok	Veri yok
Lee Eng Ng	Independent Non-Executive Director	less than a year	Veri yok	Veri yok

5.5yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 8K7 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.5 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/18 23:02
Gün Sonu Hisse Fiyatı	2024/12/18 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2024/06/30

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

UG Healthcare Corporation Limited 4 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Khang Chuen Ong	CGS International
John Cheong	Maybank Research Pte. Ltd.
Paul Chew	Phillip Securities Pte Ltd

UG Healthcare Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Ug Healthcare Corporation Limited Announces Appointment of Law Cheong Yan as Independent Non-Executive Director Chairman of Nominating Committee Member of Audit Committee Member of Remuneration Committee, Effective from December 2,2024

UG Healthcare Corporation Limited, Annual General Meeting, Oct 29, 2024

Ug Healthcare Corporation Limited Announces Retirement of Mr. Wong See Keong as Executive Director, Effective 29 October 2024

UG Healthcare Corporation Limited Announces Appointment of Ng Lee Eng as Independent Non-Executive Director Chairman of Nominating Committee Member of Audit Committee Member of Remuneration Committee

UG Healthcare Corporation Limited Announces Cessation Vincent Leow as Independent Non-Executive Director Chairman of Nominating Committee Member of Audit Committee Member of Remuneration Committee

UG Healthcare Corporation Limited, Annual General Meeting, Oct 30, 2023

Recent updates

Ug Healthcare Corporation Limited Announces Appointment of Law Cheong Yan as Independent Non-Executive Director Chairman of Nominating Committee Member of Audit Committee Member of Remuneration Committee, Effective from December 2,2024

Full year 2024 earnings released: S$0.01 loss per share (vs S$0.033 loss in FY 2023)

UG Healthcare Corporation Limited, Annual General Meeting, Oct 29, 2024

Ug Healthcare Corporation Limited Announces Retirement of Mr. Wong See Keong as Executive Director, Effective 29 October 2024

Full year 2024 earnings released: S$0.01 loss per share (vs S$0.033 loss in FY 2023)

UG Healthcare Corporation Limited to Report Fiscal Year 2024 Results on Aug 29, 2024

UG Healthcare Corporation Limited (Catalist:8K7) completed the acquisition of 50% stake in UG NITREX, S. L. from Afaprot, S. L. and Martínez for €0.5 million.

First half 2024 earnings released: S$0.008 loss per share (vs S$0.008 loss in 1H 2023)

New major risk - Revenue and earnings growth

UG Healthcare Corporation Limited to Report First Half, 2024 Results on Feb 13, 2024

UG Healthcare Corporation Limited Announces Appointment of Ng Lee Eng as Independent Non-Executive Director Chairman of Nominating Committee Member of Audit Committee Member of Remuneration Committee

New minor risk - Share price stability

UG Healthcare Corporation Limited Announces Cessation Vincent Leow as Independent Non-Executive Director Chairman of Nominating Committee Member of Audit Committee Member of Remuneration Committee

Full year 2023 earnings released: S$0.033 loss per share (vs S$0.059 profit in FY 2022)

UG Healthcare Corporation Limited, Annual General Meeting, Oct 30, 2023

Full year 2023 earnings released: S$0.033 loss per share (vs S$0.059 profit in FY 2022)

New minor risk - Financial data availability

First half 2023 earnings released: S$0.008 loss per share (vs S$0.034 profit in 1H 2022)

UG Healthcare Corporation Limited to Report First Half, 2023 Results on Feb 14, 2023

Less than half of directors are independent

UG Healthcare Corporation Limited Approves Special Cash Dividend for the Financial Year Ended 30 June 2022, Payable on 16 December 2022

UG Healthcare Corporation Limited (Catalist:8K7) entered into a share sale agreement to acquire Indigo Teguh Sdn Bhd from Lee Keck Keong for MYR 100.

Full year 2022 earnings: EPS and revenues exceed analyst expectations

UG Healthcare Corporation Limited, Annual General Meeting, Oct 28, 2022

Consensus revenue estimates fall by 12%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

UG Healthcare Corporation Limited Recommends Tax Exempt Special Dividend for Fiscal Year 2022

Less than half of directors are independent

Now 20% undervalued after recent price drop

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

UG Healthcare Corporation Limited to Report First Half, 2022 Results on Feb 11, 2022

UG Healthcare Corporation Limited to Report First Half, 2022 Results on Feb 11, 2022

Price target decreased to S$0.44

Full year 2021 earnings released: EPS S$0.19 (vs S$0.023 in FY 2020)

Price target decreased to S$0.55

Less than half of directors are independent

UG Healthcare Corporation Limited Provides Update on Covid-19 Situation in the Group's Manufacturing Division in Malaysia

Company Secretary Kar Yeoh has left the company

Third quarter 2021 earnings released: EPS S$0.056 (vs S$0.011 in 3Q 2020)

Price target decreased to S$0.99

Second quarter 2021 earnings released

UG Healthcare Corporation Limited to Report First Half, 2021 Results on Feb 04, 2021

New 90-day low: S$0.36

New 90-day low: S$0.23

New 90-day low: S$0.60

New 90-day low: S$0.64

First quarter 2021 earnings released: EPS S$0.039

Analysts update estimates

Annual earnings released: Revenue and earnings beat expectations

Full year earnings released - EPS S$0.023

Analysts increase revenue estimates to S$240.3m

UG Healthcare Corporation Limited has completed a Follow-on Equity Offering in the amount of SGD 19.0875 million.

Analysts increase revenue estimates to S$180.9m

Full year earnings released - EPS S$0.068

New 90-day high - S$2.91

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş

Şirket Analizi ve Finansal Veri Durumu

Veri Kaynakları

Analiz Modeli ve Kar Tanesi

Endüstri ve Sektör Metrikleri

Analist Kaynakları